Herpes virus special controls
This article was originally published in The Gray Sheet
Executive Summary
FDA finalizes a proposal to down-classify Type 1 and 2 herpes simplex virus serological assays from Class III to Class II medical devices in an April 3 final rule and special controls 1guidance (2"The Gray Sheet" Jan. 16, 2006, In Brief). HSV serological assays for other than Types 1 and 2 remain Class III devices...
You may also be interested in...
HSV tests down-classified
FDA 1proposed Jan. 9 to down-classify type 1 and 2 herpes simplex virus serological assays from Class III to Class II. More than 100 of the pre-amendment tests have been cleared under 510(k) applications since 1976, so there will be no practical difference in how the products are regulated once the reclassification goes through. The tests were assigned to Class III in 1982 because there was insufficient information about the herpes virus, an agency rep said...
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.